Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2015-10-09 | recombinant human interleukin-3 truncated diphtheria toxin fusion protein | Spector Consulting (France) | acute myeloid leukaemia |
Granting of the orphan status in the EU |
2015-02-23 | rituximab | Genentech, a member of Roche Group (USA - CA - Switzerland) | pemphigus vulgaris |
Granting of the orphan status in the US |
2015-03-30 | C21H27O10P | Minneamrita Therapeutics (USA - IL) | gastric cancer |
Granting of the orphan status in the US |
2015-12-29 | cyclo{-Asn-Leu-d-Phe-Al[(N5-acetyl-N5-hydroxy-Orn)-(N5-acetyl-N5-hydroxy-Orn)-(N5-hydroxy-Orn)]-} . Al(III) | Vical (USA - CA) | invasive aspergillosis |
Granting of the orphan status in the US |
2015-03-31 | bacteriophages | Ampliphi Bioscience (USA - VA) | biofilm-related bacterial infections |
Granting of a patent |
2015-12-02 | azurin-p28 | CDG Therapeutics (USA - IL) | glioma |
Granting of the orphan status in the US |
2017-03-01 | adeno-associated viral vector composed of a bioengineered AAV capsid and a codon-optimized expression cassette encoding a high-specific activity variant of human coagulation factor IX | Spark Therapeutics (USA - PA) Pfizer (USA - NY) | hemophilia B | Granting of a Fast Track status |
2015-11-16 | adeno-associated virus type 8 delivering a vector genome with human retinoschisin promoter (RS/IRBP) and the human retinoschisin cDNA (hRS) | Paul A. Sievig - National Eye Institute (USA - MD) | X-linked retinoschisis |
Granting of the orphan status in the US |
2015-12-22 | substituted imidazopyridine amide | Qurient (South Korea) | active tuberculosis |
Granting of the orphan status in the US |
2015-11-28 | oxaloacetic acid | Terra Biological (USA - CA) | amyotrophic lateral sclerosis |
Granting of the orphan status in the US |
2015-08-31 | N-acetylcysteine and sodium thiosulfate | Edward A. Neuwelt, MD Oregon Health & Science University (USA - OR) | prevention of platinum-induced toxicities in pediatric patients (0 through 16 years of age) |
Granting of the orphan status in the US |
2015-12-17 | nasal non-inhaled carbon dioxide | Capnia (USA - CA) | trigeminal neuralgia |
Granting of the orphan status in the US |
2015-12-09 | cromolyn sodium for inhalation | Patara Pharma (USA - CA) | mastocytosis | Granting of the orphan status in the US |
2015-12-02 | dodecafluoropentane emulsion - DDFPe | NuvOx Pharma (USA - AZ) | radiosensitizer to be used during radiation treatment of glioblastoma multiforme |
Granting of the orphan status in the US |
2015-12-16 | diazepam (intranasal) | Neurelis (USA - CA) | epilepsy patients who experience acute repetitive seizures |
Granting of the orphan status in the US |
2015-12-29 | fluticasone propionate | Banner Life Sciences (USA - NC) | eosinophilic esophagitis |
Granting of the orphan status in the US |
2015-12-30 | gemcitabine | Taris Biomedical (USA - MA) | upper tract urothelial carcinoma |
Granting of the orphan status in the US |
2016-03-21 | fosbretabulin tromethamine | Oxigene, now Mateon Therapeutics (USA - CA)/Diamond BioPharm (UK) | neuroendocrine tumors |
Granting of the orphan status in the EU |
2015-12-23 | magnesium lysinate bis eicosapentaenoate | Thetis Pharmaceuticals (USA - CT) | familial adenomatous polyposis |
Granting of the orphan status in the US |
2015-12-23 | imetelstat | Janssen Research & Development, a J&J company (USA - NJ) | myelodysplastic syndrome |
Granting of the orphan status in the US |
© 2024 Biopharmanalyses - Powered by Samacom+